Skip to content

Efficacy and safety of 5% minoxidil combined with microneedling in the treatment of alopecia areata of stable period: a randomized controlled trial

Efficacy and safety of 5% minoxidil combined with microneedling in the treatment of alopecia areata of stable period: a randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023751
Enrollment
Unknown
Registered
2019-06-10
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia areata

Interventions

1:Left scalp: 5% minoxidil combined with microneedling
Right scalp: 5% minoxidil
2:Right scalp: 5% minoxidil combined with microneedling
Left scalp: 5% minoxidil

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Chinese patients aged 18-50 years are enrolled in this study. They are diagnosed with alopecia areata of stable period according to the clinical features (negative in pull test) and demoscopy. Patients are required to sign the informed consents.

Exclusion criteria

Exclusion criteria: Patients with scalp disorders (such as seborrheic dermatitis, psoriasis or eczema) or other hair diseases(such as androgenetic alopecia, telogen effluvium or anagen effluvium); pregnant or lactating women; allergic to minoxidil; previous topical minoxidil treatment within the past 12 weeks; drug or alcohol abuse; mental diseases or comprehension disorder; undergoing hormonotherapy, phototherapy or physiotherapy; wearing a wig; hair transplantation on the target areas; anemia; ferritin is below 40ug/L; autoimmune diseases; endocrine diseases (such as diabetes, thyroid or pituitary diseases); severe systemic diseases; malignant tumor; hair loss induced by chemotherapeutic drugs; recent craniocerebral operation; participants of other clinical trials within last 3 months.

Design outcomes

Primary

MeasureTime frame
SALT Score for alopecia areata;

Secondary

MeasureTime frame
Sinclair Grade;Dermatology life quality index;

Countries

China

Contacts

Public ContactYang Qinping

Huashan Hospital, Fudan University

qpyang_shhs1@126.com+86 13601927866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026